GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » PetMed Express Inc (NAS:PETS) » Definitions » Sloan Ratio %

PetMed Express (PetMed Express) Sloan Ratio % : 18.02% (As of Dec. 2023)


View and export this data going back to 1997. Start your Free Trial

What is PetMed Express Sloan Ratio %?

Richard Sloan from the University of Michigan was first to document what is referred to as the "accrual anomaly". His 1996 paper found that shares of companies with small or negative accruals vastly outperform (+10%) those of companies with large ones.

PetMed Express's Sloan Ratio for the quarter that ended in Dec. 2023 was 18.02%.

As of Dec. 2023, PetMed Express has a Sloan Ratio of 18.02%, indicating there is a warning stage of accrual build up.


PetMed Express Sloan Ratio % Historical Data

The historical data trend for PetMed Express's Sloan Ratio % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

PetMed Express Sloan Ratio % Chart

PetMed Express Annual Data
Trend Mar14 Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23
Sloan Ratio %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -4.39 -6.88 -7.32 1.10 -7.41

PetMed Express Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Sloan Ratio % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -5.60 -7.59 11.38 10.71 18.02

Competitive Comparison of PetMed Express's Sloan Ratio %

For the Pharmaceutical Retailers subindustry, PetMed Express's Sloan Ratio %, along with its competitors' market caps and Sloan Ratio % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


PetMed Express's Sloan Ratio % Distribution in the Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, PetMed Express's Sloan Ratio % distribution charts can be found below:

* The bar in red indicates where PetMed Express's Sloan Ratio % falls into.



PetMed Express Sloan Ratio % Calculation

Earnings contain a lot of non cash earnings which is called accruals. The Sloan ratio is a way to identify firms with low non-cash or accrual-derived earnings relative to their cash flow.

PetMed Express's Sloan Ratio for the fiscal year that ended in Mar. 2023 is calculated as

Sloan Ratio=(Net Income (A: Mar. 2023 )-Cash Flow from Operations (A: Mar. 2023 )
-Cash Flow from Investing (A: Mar. 2023 ))/Total Assets (A: Mar. 2023 )
=(5.14-27.803
--10.26)/167.478
=-7.41%

PetMed Express's Sloan Ratio for the quarter that ended in Dec. 2023 is calculated as

Sloan Ratio=(Net Income (TTM)-Cash Flow from Operations (TTM))
-Cash Flow from Investing (TTM))/Total Assets (Q: Dec. 2023 )
=(-3.2-6.916
--41.35)/173.35
=18.02%

PetMed Express's Net Income for the trailing twelve months (TTM) ended in Dec. 2023 was -0.216 (Mar. 2023 ) + -0.887 (Jun. 2023 ) + -0.07 (Sep. 2023 ) + -2.027 (Dec. 2023 ) = $-3.2 Mil.
PetMed Express's Cash Flow from Operations for the trailing twelve months (TTM) ended in Dec. 2023 was 9.724 (Mar. 2023 ) + 0.562 (Jun. 2023 ) + -0.777 (Sep. 2023 ) + -2.593 (Dec. 2023 ) = $6.9 Mil.
PetMed Express's Cash Flow from Investing for the trailing twelve months (TTM) ended in Dec. 2023 was -1.931 (Mar. 2023 ) + -37.012 (Jun. 2023 ) + -0.984 (Sep. 2023 ) + -1.423 (Dec. 2023 ) = $-41.4 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


PetMed Express  (NAS:PETS) Sloan Ratio % Explanation

A former University of Michigan researcher, Richard Sloan's 1996 paper found that shares of companies with small or negative accruals vastly outperform (+10%) those of companies with large ones. In fact, for the 40-year period between 1962 and 2001, buying the lowest accrual companies and shorting the highest accrual companies resulted in an average annual compounded return of 18%, more than double the S&P 500's 7.4% annual return over the same period.

According to How to Beat the Market with the Sloan Ratio:

If the Sloan Ratio is between -10% and 10%, the company is in the safe zone and there is no funny business with accruals.

If the Sloan Ratio is less than between -25% and -10% on the negative side, and between 10% and 25% on the positive side, this is a warning stage of accrual build up.

If the Sloan Ratio is less than -25% or greater than 25%, and this ratio is consistent over several quarters or even years, be careful. Earnings are highly likely to be made up of accruals.

As of Dec. 2023, PetMed Express has a Sloan Ratio of 18.02%, indicating there is a warning stage of accrual build up.


PetMed Express Sloan Ratio % Related Terms

Thank you for viewing the detailed overview of PetMed Express's Sloan Ratio % provided by GuruFocus.com. Please click on the following links to see related term pages.


PetMed Express (PetMed Express) Business Description

Traded in Other Exchanges
Address
420 South Congress Avenue, Suite 100, Delray Beach, FL, USA, 33445
PetMed Express Inc along with its subsidiaries is a nationwide pet pharmacy. The company markets prescription and non-prescription pet medications, health products, and supplies for dogs and cats, direct to the consumer. The company generates its revenue by selling pet medications and pet supplies primarily to retail consumers.
Executives
Gian Fulgoni director
Christine Chambers officer: CFO 1501 1ST AVENUE SOUTH, STE. 600, SEATTLE WA 98134
Mathew N Hulett director, officer: CEO & President 1621 NORTH KENT STREET, SUITE 1200, ARLINGTON VA 22209
Campbell Leslie C.g. director C/O COUPA SOFTWARE INC., 1855 S. GRANT STREET, SAN MATEO CA 94402
Diana G Purcel director C/O FAMOUS DVES OF AMERICA INC, 8091 WALLACE ROAD, EDEN PRAIRIE MN 55344
Moseley Mark Bradley Jr other: Chief Technology Info Officer 420 SOUTH CONGRESS AVE., DELRAY BEACH FL 33445
Daniel Job Pingree other: Chief Marketing Officer 420 SOUTH CONGRESS AVE., DELRAY BEACH FL 33445
Sandra Yvette Campos director 4900 E DUBLIN GRANVILLE RD, COLUMBUS OH 43081
Jacqueline Paula Smith other: Vice President of People 420 SOUTH CONGRESS AVE., DELRAY BEACH FL 33445
Carolyn Carden other: VP of Product 420 SOUTH CONGRESS AVE., DELRAY BEACH FL 33445
Peter Cobb director DSW, INC., 810 DSW DRIVE, COLUMBUS OH 43219
Jodi Watson director 420 SOUTH CONGRESS AVE., DELRAY BEACH FL 33445
Frank J Formica director 1441 S.W. 29TH AVENUE, POMPANO BEACH FL 33069
Bruce S Rosenbloom officer: Chief Financial Officer 6401 CONGRESS AVENUE, SUITE 250, BOCA RATON FL 33487
Menderes Akdag director, officer: Chief Executive Officer 1441 S.W. 29TH AVENUE, POMPANO BEACH FL 33069